• 1
    Nebel OT, Forbes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 9536.
  • 2
    Katz PO & Castell DO. Current medical treatment and indications for surgical referral for gastroesophageal reflux disease (GERD). Semin Thoracic Cardiovasc Surg 1997; 9: 16972.
  • 3
    Hetzel DJ, Dent J, Reed WD, et al.Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 90312.
  • 4
    DeMeester TR, Johnson LF, Guy JJ, et al.Patterns of gastroesophageal reflux in health and disease. Ann Surg 1976; 184: 45970.
  • 5
    Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 7637.
    Direct Link:
  • 6
    Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 13359.
  • 7
    Hatlebakk JG, Katz PO, Kuo B, Castell DO. Medical therapy: management of the refractory patient. Gastroenterol Clin North Am 1999; 28: 84760.
  • 8
    Bell NJY, Birget D, Howden CW, et al.Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51: 5967.
  • 9
    Ladas SD, Tassios PS, Raptis SA. Selection of patients for successful maintenance treatment of esophgitis with low-dose omeprazole: Use of 24-hour gastric pH monitoring. Am J Gastroenterol 2000; 95: 37480.
  • 10
    DeVault KR. Overview of medical therapy for gastroesophageal reflux disease. Gastroenterol Clin North Am 1999; 28: 83146.
  • 11
    Cerderberg C, Thomson ABR, Mahachai V, et al.Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 9138.
  • 12
    Sanders SW, Tolman KG, Greski PA, et al.The effects of lansoprazole, a new H+,K+-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992; 6: 35972.
  • 13
    Cerderberg C, Rohhs K, Lundborg P, et al.Effects of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28: 17984.
  • 14
    Tutuian R, Katz PO, Castell DO. A PPI is a PPI. Lessons from prolonged intragastric pH monitoring. Gastroenterology 2000; 118(4): A17A17[Abstract].
  • 15
    Achem SR, Kolts BE, MacMath T, et al.Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42: 213845.
  • 16
    Katz PO & Castell DO. Medical therapy of supraesophageal reflux disease. Am J Med 2000; 108(4A): 170S177S.
  • 17
    Harding SM, Richter JE, Bradley LA, et al. Asthma and gastroesophageal reflux: acid suppression therapy improves asthma outcome. Am J Med 1996; 100: 395405.
  • 18
    Kuo B & Castell DO. Optimal dosing of omeprazole 40mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 15328.
  • 19
    Katz PO, Anderson C, Khoury R, Castell DO. Gastro-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 12314.
  • 20
    Fouad YM, Katz PO, Castell DO. Esophageal motility defects associated with nocturnal gastro-esophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1998; 13: 146771.DOI: 10.1046/j.1365-2036.1999.00641.x
  • 21
    Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett’s esophagus: feasible and effective. Aliment Pharmacol Ther 2001; in press.